(AOF) – Dupixent “made it possible to significantly reduce exacerbations of COPD” or “chronic obstructive pulmonary disease” in the context of a second positive phase III trial: these results “help accelerate submission to the FDA” and confirm that this drug “has the potential to become the first biologic approved for the treatment of this serious disease.” This is what Sanofi announces about its flagship drug already approved in the treatment of other conditions.
Sanofi recalls that Dupixent has been approved in one or more countries for the treatment of atopic dermatitis, asthma, nasal polyposis, eosinophilic esophagitis or prurigo nodular in certain categories of patients of different ages.
The drug is currently approved for one or more of these indications “in more than 60 countries, including countries in the European Union, the United States and Japan” and “more than 750,000 patients worldwide are treated with this medicine”.
© 2023 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
